For example, a previous study reported that an NSCLC patient with acquired BRAF-V600E mutation resistance to osimertinib responded to combination therapy consisting of osimertinib, dabrafenib, and trametinib [41]. Here, BRAF is linked to non-small cell lung carcinoma.